<DOC>
	<DOCNO>NCT02184039</DOCNO>
	<brief_summary>Study evaluate efficacy safety meloxicam ( Mobicox® ) Mexican population rheumatic disease .</brief_summary>
	<brief_title>Efficacy Safety Meloxicam ( Mobicox® ) Mexican Population With Rheumatic Diseases</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Rheumatic Diseases</mesh_term>
	<mesh_term>Collagen Diseases</mesh_term>
	<criteria>Hypersensitivity meloxicam NSAIDS History asthma , angioedema urticaria secondary NSAIDS Pregnancy lactation Recent current history peptic ulcer disease , severe renal failure , severe hepatic failure Age 12 year .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>